CLINICAL VALUE OF CELL CONTENT WITH ISOLATED INTERSTITIAL DELETION 13q14 IN CHRONIC LYMPHATIC LEUKEMIA
https://doi.org/DOI 10.15372/SSMJ20190103
Abstract
Currently, it is urgent to search for new prognostic factors that improve the stratification of patients into risk groups and allow the determination of indications for various CLL therapy programs with the aim of increasing their clinical effectiveness.
Material and methods. The research presents the data on chromosomal aberrations with the help of the FISH method in 224 CLL patients during the diagnosis, among them 49 patients are in stage A, 166 patients – in stage B and 29 patients – in stage C.
Results and discussion. Chromosomal abnormalities were detected in 176 (72 %) patients. The most frequent aberration in CLL was del13q14, which was found in 124 (51 %) patients and occurred alone or in combination with other chromosomal changes. As the only chromosomal abnormality, del13q14 was found in 77 patients who differed from each other in the number of tumor cells that had isolated del13q14. We have studied the prognostic value of the content of tumor cells with isolated 13q14 deletion in CLL patients during the diagnosis. A comparative analysis of 2 groups of patients who had the percentage of leukemia cells with this deletion (it was ≥ 60 % or < 60 %) was conducted. It has been established that the number of cells with isolated del13q14 is an independent predictor of survival, free from treatment, as well as the overall survival of CLL patients and may serve as an additional prognostic factor.
About the Authors
T. P. Zagoskina
Kirov State Medical University of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Tamara Pavlovna ZAGOSKINA – candidate of medical sciences, assistant professor of the department of hospital therapy
610998, Kirov, Karl Marks str., 112
E. N. Zotina
Кировский НИИ гематологии и переливания крови ФМБА России
Russian Federation
Russian Federation
Ekaterina Nikolaevna ZOTINA – candidate of medical sciences, head of the scientific and clinical department of hematology, chemotherapy and bone marrow transplantation
610027, Kirov, Krasnoarmeyskaya str., 72
References
1. Dal Bo M., Rossi F.M., Rossi D., Deambrogi C., Bertoni F., Del Giudice I., Palumbo G., Nanni M., Rinaldi A., Kwee I., Tissino E., Corradini G., Gozzetti A., Cencini E., Ladetto M., Coletta A.M., Luciano F., Bulian P., Pozzato G., Laurenti L., Forconi F., Di Raimondo F., Marasca R., Del Poeta G., Gaidano G., Foa R., Guarini A., Gattei V. 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia // Genes Chromosomes Cancer. 2011. 50. (8). 633-643.
2. Döhner H., Stilgenbauer S., Benner A., Leupolt E., Kröber A., Bullinger L., Döhner K., Bentz M., Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia // N. Engl. J. Med. 2000. 343. (26). 1910–1916.
3. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Döhner H., Hillmen P., Keating M., Montserrat E., Chiorazzi N., Stilgenbauer S., Rai K.R., Byrd J.C., Eichhorst B., O'Brien S., Robak T., Seymour J.F., Kipps T.J. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL // Blood. 2018. 131. (25). 2745-2760.
4. Hernandez J.A., Rodriguez A.E., Gonzalez M., Benito R., Fontanillo C., Sandoval V., Romero M., Martin-Nunez G., de Coca A.G., Fisac R., Galende J., Recio I., Ortuno F., Garcia J.L., de las Rivas J., Gutierrez N.C., San Miguel J.F., Hernandez J.M. A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia // Haematologica. 2009. 94. (3). 364-371.
5. Hruba M., Subrt I. Multiclonal monoallelic 13q14 interstitial deletion in chronic lymphocytic leukemia // Leuk. Lymphoma. 2013. 54. (2). 413-416.
6. Janssens A., Van Roy N., Poppe B., Noens L., Philippe J., Speleman F., Offner F. High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature // Eur. J. Haematol. 2012. 89 (1). 72-80.
7. Ouillette P., Collins R., Shakhan S., Li J., Li C., Shedden K., Malek S.N. The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia // Clin. Cancer Res. 2011. 17. (21). 6778-6790.
8. Ouillette P., Erba H., Kujawski L., Kaminski M., Shedden K., Malek S.N. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14 // Cancer Res. 2008. 68. (4). 1012–1021.
9. Rodriguez-Vicente A.E., Diaz M.G., Hernandez-Rivas J.M. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease // Cancer Genet. 2013. 206 (3). 49-62.
10. Van Dyke D.L., Shanafelt T.D., Call T.G., Zent C.S., Smoley S.A., Rabe K.G., Schwager S.M., Sonbert J.C., Slager S.L., Kay N.E. A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia // Br. J. Haematol. 2010. 148. (4). 544-550.
11. Yi S., Li H., Li Z., Хiong W., Liu H., Liu W., Lv R., Yu Z., Zou D., Xu Y., An G., Qiu L. The prognostic significance of 13q deletions of different sizes in patients with B-cell chronic lymphoproliferative disorders: a retrospective study // Int. J. Hematol. 2017. 106. (3). 418-425.
12. Zenz T., Döhner H., Stilgenbauer S. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia // Best Pract. Res. Clin. Haematol. 2007. 20. (3). 439-453.
Review
Views:
570
Email this article 